The company is pleased to announce that Qlife, in collaboration with its strategic partner Hipro Biotechnology, has developed a new Egoo Health product platform, which is already CE-IVD-marked. As a result, sales can commence immediately in the EU.

Qlife and Hipro Biotechnology have joined forces to introduce a jointly developed, CE-IVD-marked platform to the market. This new solution combines the best of Hipro’s technology with Egoo Health’s innovations. It is based on Hipro’s already CE-IVD-marked Palm F product line, enhanced by Qlife’s high-tech Egoo optics, plasma-filtration, expertise, and cloud-analytics data management.

This new platform will be focused on the field of Women’s Health and initially includes 7 high-sensitivity hormone tests related to fertility and menopause. Additionally, the company expects to introduce more interesting biomarker tests during the year.

“This development represents a quantum leap for our company. We were amazed to discover that by joining forces and making some upgrades, we could suddenly offer a lab-grade product with biomarkers addressing an unmet need on an already CE-IVD-marked, high-sensitivity platform. In doing so, we have circumvented the lengthy and resource-intensive process of obtaining regulatory approval for each biomarker test, giving us a substantial new Egoo product line featuring biomarkers currently inaccessible to layperson to continuously monitor. In my opinion, this is a breakthrough for the company. We can now focus on sales, marketing, and the educational aspects of introducing this product to the market.”- says Thomas Warthoe, CEO of Qlife.

“Accurate assessments of fertility, late reproductive age, and the menopausal transition are crucial areas that remain somewhat underserved. With this new product line, women can over longer periods of time continuously monitor and obtain precise insights into their hormonal balance, either in the comfort of their own home or alongside a professional. Of course, interpreting the results requires some level of expertise. We are currently developing a specialized AI feature to facilitate this process, which we will share more information about soon.” – says Peter Warthoe, CSO of Qlife

The women’s health biomarkers initially launched on the new platform are:

1. Progesterone (PROG)
2. Luteinizing Hormone (LH)
3. Follicle-Stimulating Hormone (FSH)
4. Anti-Müllerian Hormone (AMH)
5. Prolactin (PRL)
6. Beta-Human Chorionic Gonadotropin (β–HCG)
7. Thyroid Stimulating Hormone (TSH)

During the first half of February, the product line and additional information will be available on the Egoo Health website. The product line is expected to be marketed with a focus on own digital marketing, combined with entering commercial partnerships.

This introduction marks a major step for Qlife in its ongoing transformation from an R&D-focused company to an organization with a substantial product portfolio, aiming to be a first mover in the emerging home diagnostics market. Additionally, it further strengthens Qlife’s ties with its strategic partner, Hipro Biotechnology.

This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 2025-01-16 09:00 CET

For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34

About Egoo Health

Egoo Health enables advanced clinical-grade biomarker testing at home. The aim is to give people access to important health data at the clinical-grade level. Egoo Health is an integrated platform, consisting of a small diagnostic device, a blood-to-plasma collector, a disposable capsule that contain test reagents for a specific biomarker and the Egoo smartphone app that operates the system and can share data with health authorities.